Osteosarcoma - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 223 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Osteosarcoma - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Osteosarcoma - Pipeline Review, H2 2016', provides an overview of the Osteosarcoma pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Osteosarcoma
- The report reviews pipeline therapeutics for Osteosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects
- The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Osteosarcoma

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Osteosarcoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Osteosarcoma Overview 11
Therapeutics Development 12
Pipeline Products for Osteosarcoma - Overview 12
Pipeline Products for Osteosarcoma - Comparative Analysis 13
Osteosarcoma - Therapeutics under Development by Companies 14
Osteosarcoma - Therapeutics under Investigation by Universities/Institutes 16
Osteosarcoma - Pipeline Products Glance 17
Clinical Stage Products 17
Early Stage Products 18
Osteosarcoma - Products under Development by Companies 19
Osteosarcoma - Products under Investigation by Universities/Institutes 20
Osteosarcoma - Companies Involved in Therapeutics Development 21
Advaxis, Inc. 21
Amgen Inc. 22
AVEO Pharmaceuticals, Inc. 23
Bayer AG 24
Bellicum Pharmaceuticals, Inc. 25
Celldex Therapeutics, Inc. 26
CytRx Corporation 27
Eleison Pharmaceuticals LLC 28
Exelixis, Inc. 29
Isofol Medical AB 30
MediaPharma s.r.l. 31
Merck & Co., Inc. 32
Merrimack Pharmaceuticals, Inc. 33
Netris Pharma S.A.S. 34
Novartis AG 35
Oncolys BioPharma Inc 36
Pfizer Inc. 37
Shionogi & Co., Ltd. 38
Teijin Pharma Limited 39
United Therapeutics Corporation 40
Osteosarcoma - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
3D-QM - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
3D-QMS - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
ADXS-HER2 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
aldoxorubicin hydrochloride - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
AM-7209 - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
AU-101 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
AV-203 - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
axitinib - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
cabozantinib s-malate - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
celyvir - Drug Profile 106
Product Description 106
Mechanism Of Action 106
R&D Progress 106
CGS-200 - Drug Profile 107
Product Description 107
Mechanism Of Action 107
R&D Progress 107
cisplatin SR - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
dihydroartemisinin - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
dinutuximab - Drug Profile 111
Product Description 111
Mechanism Of Action 111
R&D Progress 111
everolimus - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
glembatumumab vedotin - Drug Profile 125
Product Description 125
Mechanism Of Action 125
R&D Progress 125
irinotecan hydrochloride - Drug Profile 130
Product Description 130
Mechanism Of Action 130
R&D Progress 130
ligerin - Drug Profile 141
Product Description 141
Mechanism Of Action 141
R&D Progress 141
LLL-12 - Drug Profile 142
Product Description 142
Mechanism Of Action 142
R&D Progress 142
Modufolin - Drug Profile 143
Product Description 143
Mechanism Of Action 143
R&D Progress 143
Monoclonal Antibody for Osteosarcoma - Drug Profile 145
Product Description 145
Mechanism Of Action 145
R&D Progress 145
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile 146
Product Description 146
Mechanism Of Action 146
R&D Progress 146
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile 147
Product Description 147
Mechanism Of Action 147
R&D Progress 147
MPE-8.3 - Drug Profile 149
Product Description 149
Mechanism Of Action 149
R&D Progress 149
NP-137 - Drug Profile 150
Product Description 150
Mechanism Of Action 150
R&D Progress 150
OBP-702 - Drug Profile 151
Product Description 151
Mechanism Of Action 151
R&D Progress 151
Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile 152
Product Description 152
Mechanism Of Action 152
R&D Progress 152
pazopanib hydrochloride - Drug Profile 153
Product Description 153
Mechanism Of Action 153
R&D Progress 153
pembrolizumab - Drug Profile 160
Product Description 160
Mechanism Of Action 160
R&D Progress 160
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 191
Product Description 191
Mechanism Of Action 191
R&D Progress 191
radium Ra 223 dichloride - Drug Profile 193
Product Description 193
Mechanism Of Action 193
R&D Progress 193
RSF-101 - Drug Profile 202
Product Description 202
Mechanism Of Action 202
R&D Progress 202
S-588410 - Drug Profile 203
Product Description 203
Mechanism Of Action 203
R&D Progress 203
SEN-461 - Drug Profile 205
Product Description 205
Mechanism Of Action 205
R&D Progress 205
Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma - Drug Profile 206
Product Description 206
Mechanism Of Action 206
R&D Progress 206
Small Molecules to Inhibit CaMKII for Osteosarcoma - Drug Profile 207
Product Description 207
Mechanism Of Action 207
R&D Progress 207
T-2GES - Drug Profile 208
Product Description 208
Mechanism Of Action 208
R&D Progress 208
Vaccine for Osteosarcoma - Drug Profile 209
Product Description 209
Mechanism Of Action 209
R&D Progress 209
Osteosarcoma - Dormant Projects 210
Osteosarcoma - Discontinued Products 212
Osteosarcoma - Product Development Milestones 213
Featured News & Press Releases 213
Apr 28, 2016: FDA Grants Advaxis Fast Track Designation for ADXS-HER2 for Patients with Newly-Diagnosed, Non-Metastatic, Surgically-Resectable Osteosarcoma 213
Apr 20, 2016: Celldex Therapeutics Presents Data Supporting the Clinical Development of Glembatumumab Vedotin at the AACR Annual Meeting 2016 213
Apr 13, 2016: Sarcoma Foundation of America Honors Advaxis for Advancements in Immunotherapy Platform 214
Mar 23, 2016: Advaxis Hosts Research Reception to Review Late-Breaking ADXS-HER2 at AACR Abstract 215
Mar 21, 2016: Survival Results with Advaxis HER2 Targeted Immunotherapy in Canine Osteosarcoma Published in Clinical Cancer Research 215
Mar 16, 2016: Merrimack to Present on ONIVYDE (irinotecan liposome injection) at the 2016 American Association for Cancer Research Annual Meeting 216
Jan 19, 2016: Advaxis Expands Intellectual Property for Lm Technology Platform 216
Dec 01, 2015: Advaxis Receives Orphan Drug Designation in the European Union for ADXS-HER2 for the Treatment of Osteosarcoma 217
Nov 30, 2015: CapGenesis Files Five Orphan Drug Designation Requests with the FDA and EMA for CGS-200 as a Topical Analgesic 217
Jul 21, 2015: Advaxis Expands Intellectual Property for Lm Technology Platform in HER2 218
May 04, 2015: CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 219
May 01, 2015: Eleison Announces Successful Completion of Stage 1 of its Phase II Trial of ILC (Inhaled Lipid-complexed Cisplatin) for Pediatric Bone Cancer 220
Apr 28, 2015: Advaxis Enhances Lm-LLO Cancer Immunotherapy Intellectual Property With USPTO Patent Addressing ADXS-HER2 220
Nov 04, 2014: Advaxis to Present Data of ADXS-cHER2 at the Society for Immunotherapy of Cancer 29th Annual Meeting 221
Appendix 222
Methodology 222
Coverage 222
Secondary Research 222
Primary Research 222
Expert Panel Validation 222
Contact Us 222
Disclaimer 223

List of Tables

Number of Products under Development for Osteosarcoma, H2 2016 12
Number of Products under Development for Osteosarcoma - Comparative Analysis, H2 2016 13
Number of Products under Development by Companies, H2 2016 15
Number of Products under Investigation by Universities/Institutes, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Investigation by Universities/Institutes, H2 2016 20
Osteosarcoma - Pipeline by Advaxis, Inc., H2 2016 21
Osteosarcoma - Pipeline by Amgen Inc., H2 2016 22
Osteosarcoma - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 23
Osteosarcoma - Pipeline by Bayer AG, H2 2016 24
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 25
Osteosarcoma - Pipeline by Celldex Therapeutics, Inc., H2 2016 26
Osteosarcoma - Pipeline by CytRx Corporation, H2 2016 27
Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H2 2016 28
Osteosarcoma - Pipeline by Exelixis, Inc., H2 2016 29
Osteosarcoma - Pipeline by Isofol Medical AB, H2 2016 30
Osteosarcoma - Pipeline by MediaPharma s.r.l., H2 2016 31
Osteosarcoma - Pipeline by Merck & Co., Inc., H2 2016 32
Osteosarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016 33
Osteosarcoma - Pipeline by Netris Pharma S.A.S., H2 2016 34
Osteosarcoma - Pipeline by Novartis AG, H2 2016 35
Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H2 2016 36
Osteosarcoma - Pipeline by Pfizer Inc., H2 2016 37
Osteosarcoma - Pipeline by Shionogi & Co., Ltd., H2 2016 38
Osteosarcoma - Pipeline by Teijin Pharma Limited, H2 2016 39
Osteosarcoma - Pipeline by United Therapeutics Corporation, H2 2016 40
Assessment by Monotherapy Products, H2 2016 41
Number of Products by Stage and Target, H2 2016 43
Number of Products by Stage and Mechanism of Action, H2 2016 46
Number of Products by Stage and Route of Administration, H2 2016 49
Number of Products by Stage and Molecule Type, H2 2016 51
Osteosarcoma - Dormant Projects, H2 2016 210
Osteosarcoma - Dormant Projects (Contd..1), H2 2016 211
Osteosarcoma - Discontinued Products, H2 2016 212